• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    PureTech Health plc - American Depositary Shares (NQ:PRTC)

    16.90 -0.13 (-0.76%)
    Streaming Delayed Price Updated: 12:55 PM EDT, May 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about PureTech Health plc - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    PureTech Announces Annual Results for Year Ended December 31, 2025
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech to Present at the Leerink Partners Global Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Appoints Robert Lyne as Chief Executive Officer
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Health plc – Half-Year Report
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Health: Notice of Half-Yearly Results
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Leadership Transition
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Announces Board Change
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech Health: Results of Annual General Meeting
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech to Present at the Jefferies Global Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
    From PureTech
    Via Business Wire
    News headline image
    PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
    From PureTech Health plc
    Via Business Wire
    News headline image
    PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
    From PureTech Health plc
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.